No label defined (Q28366611)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	No label defined	scientific article

Statements

scholarly article

0 references

High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome (English)

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

G Somlo

1

0 references

J H Doroshow

2

0 references

T Synold

3

0 references

J Longmate

4

0 references

D Reardon

5

0 references

W Chow

6

0 references

S J Forman

7

0 references

L A Leong

8

0 references

K A Margolin

9

0 references

R J Morgan

10

0 references

J W Raschko

11

0 references

S I Shibata

12

0 references

M L Tetef

13

0 references

Y Yen

14

0 references

N Kogut

15

0 references

J Schriber

16

0 references

J Alvarnas

17

0 references

language of work or name

0 references

publication date

15 June 2001

0 references

British Journal of Cancer

0 references

84

0 references

12

0 references

1591-8

0 references

Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

29 September 2017

Anthracycline dose intensity: clinical pharmacology and pharmacokinetics of high-dose doxorubicin administered as a 96-hour continuous intravenous infusion.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

29 September 2017

Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

29 September 2017

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

29 September 2017

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

29 September 2017

Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

29 September 2017

Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

2 June 2018

High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

2 June 2018

High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

2 June 2018

Analysis of anticancer drugs in biological fluids: determination of taxol with application to clinical pharmacokinetics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

2 June 2018

A phase I trial of taxol given by a 6-hour intravenous infusion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

2 June 2018

Paclitaxel-containing high-dose chemotherapy in high-risk breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

27 November 2018

Paclitaxel induces programmed cell death in MDA-MB-468 human breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

27 November 2018

Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

27 November 2018

High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

27 November 2018

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363687

27 November 2018

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/11401310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04]

1 reference

https://pubmed.ncbi.nlm.nih.gov/11401310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Loop-column extraction and liquid chromatographic analysis of doxorubicin and three metabolites in plasma

1 reference

https://pubmed.ncbi.nlm.nih.gov/11401310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11401310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/11401310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/11401310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/11401310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/11401310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America

1 reference

https://pubmed.ncbi.nlm.nih.gov/11401310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11401310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement

1 reference

https://pubmed.ncbi.nlm.nih.gov/11401310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I trial of high-dose paclitaxel, cyclophosphamide and mitoxantrone with autologous blood stem cell support for the treatment of metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/11401310

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1054/BJOC.2001.1835

0 references

Dimensions Publication ID

0 references

release_p6l6riluhfecbk56js3ak73tcu

1 reference

https://api.fatcat.wiki/v0/release/p6l6riluhfecbk56js3ak73tcu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28366611&oldid=2175250393"